Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06617416 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of AK104 in Subjects With Unresectable Locally Advanced NSCLC

Name: A Study of AK104 in Subjects With Unresectable Locally Advanced NSCLC — clinical trial record (NCT06617416)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 3

SponsorAkeso

Started2024-11-12

View on ClinicalTrials.gov ↗

Amendment history

2025-03-11

Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v1

Trial statusNot Yet Recruiting→Recruiting

Start dateestimated 2024-09-30→confirmed 2024-11-12

Study sitesdetails revised at 1 of 1 site

2024-09-25

Original filing

Akeso

96 trials monitored

See 1 trial at risk

Lung Cancer

4,033 trials monitored

See 210 trials at risk

Non-Small Cell Lung Cancer (NSCLC)

2,914 trials monitored

See 156 trials at risk

This study compares the efficacy and safety of AK104 versus Sugemalimab as consolidation therapy in patients with unresectable, locally advanced NSCLC who have not progressed following concurrent or sequential chemoradiotherapy.

Trial Details

NCT Number	NCT06617416
Lead Sponsor	Akeso
Conditions	NSCLC (Non-small Cell Lung Cancer)
Enrollment	560 participants
Start Date	2024-11-12
Primary Completion	2026-10-28 (estimated)
Study Completion	2028-12-30 (estimated)
Updated on ClinicalTrials.gov	2025-03-12